“Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s96, https://doi.org/10.25251/skin.4.supp.96.